Cryoport, Inc.
Cryoport provides temperature-controlled supply chain services and products for life sciences customers, including biopharmaceutical and pharmaceutical companies, animal health markets, reproductive medicine, academic institutions, research organizations and government agencies. Its services support the storage, handling and delivery of biological materials, with particular focus on cell and gene therapies. The company is headquartered in Brentwood, Tennessee. Cryoport operates through Life Sciences Services and Life Sciences Products. Life Sciences Services includes temperature-controlled transport, biostorage, bioservices such as kitting, labeling and fulfillment, and cryopreservation services offered through IntegriCell. Life Sciences Products consists of cryogenic systems manufacturing through MVE Biological Solutions, which makes freezers, dewars and transport systems. Cryoport earns money by providing these services and selling cryogenic equipment. Its operations also use the Cryoportal digital logistics management platform to coordinate and monitor supply chain activity.
No SEC Form 4 filings for $CYRX in the last 30 days.
See all $CYRX insider activity →Keybanc raised its price target for CryoPort to $20 from $17, representing a 17.6% increase. The new target suggests a 24.6% upside from the Nov 5 close of $16.05. The firm maintained its Overweight rating on the stock.
Needham raised its price target for CryoPort (NASDAQ:CYRX) to $28 from $19, citing strong Q3 2026 revenue performance and raised full-year guidance. The company reported 14% year-over-year revenue growth to $50.2M, exceeding estimates, but posted a wider-than-expected loss of $0.25 per share. Needham maintains a Buy rating, expecting further upside in 2027.
Cryoport (CYRX) reported Q3 2026 revenue of $50.2M, up 14% YoY, with life sciences services growing 18%. The company raised its full-year revenue outlook to $197M-$199M. Cryoport supports 23 commercial therapies and has a record 788 clinical trials, with 2 potential new therapy approvals expected in Q4. The company achieved ISO certifications and received industry awards.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning CYRX (Cryoport, Inc.). Coverage has skewed bullish: 6 bullish, 1 neutral, and 0 bearish.
Recent CYRX coverage spans earnings and financial news.
Keybanc raised its price target for CryoPort to $20 from $17, representing a 17.6% increase. The new target suggests a 24.6% upside from the Nov 5 close of $16.05. The firm maintained its Overweight rating on the stock.
Analyst upgrade suggests bullish outlook.
Guidance lift suggests stronger demand and may push the stock higher.
Guidance is cautious amid regulatory uncertainty, likely limiting upside in the near term.
Guidance raise suggests stronger demand for cell and gene therapy logistics, likely supporting the stock.
AlphAI scores every news story that mentions CYRX with an AI model for sentiment and relevance, and aggregates insider trades from Cryoport, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Keybanc raised its price target for CryoPort to $20 from $17, representing a 17.6% increase. The new target suggests a 24.6% upside from the Nov 5 close of $16.05. The firm maintained its Overweight rating on the stock.
Needham raised its price target for CryoPort (NASDAQ:CYRX) to $28 from $19, citing strong Q3 2026 revenue performance and raised full-year guidance. The company reported 14% year-over-year revenue growth to $50.2M, exceeding estimates, but posted a wider-than-expected loss of $0.25 per share. Needham maintains a Buy rating, expecting further upside in 2027.
Cryoport (CYRX) reported Q3 2026 revenue of $50.2M, up 14% YoY, with life sciences services growing 18%. The company raised its full-year revenue outlook to $197M-$199M. Cryoport supports 23 commercial therapies and has a record 788 clinical trials, with 2 potential new therapy approvals expected in Q4. The company achieved ISO certifications and received industry awards.
CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.
Cryoport reported Q3 2026 revenue of $50.2M, up 14% YoY. Commercial cell and gene therapy revenue grew 20%. The company raised full-year revenue guidance to $197M-$199M. Cryoport supports 788 global clinical trials and 23 approved therapies. Adjusted EBITDA was $1.1M, marking progress toward profitability.
BTIG maintained a Buy rating on CryoPort with a $26 price target, implying 54.4% upside from the Oct 12 close. The firm cites strong revenue growth prospects due to the expanding cell and gene therapy market and CryoPort's leadership in cold-chain logistics.
BTIG maintained a Buy rating on CryoPort with a $25 price target, suggesting a 49% upside from its Sep 17 close. The company reported positive adjusted EBITDA for the first time since Q1 2023 and 15% year-over-year revenue growth in its Life Sciences Services segment. CryoPort supports 22 approved therapies and expects further growth from new facilities and clinical trials.
Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.
Conestoga Capital Advisors’ Q2 2026 investor letter highlighted Cryoport, Inc. (NASDAQ:CYRX), citing broad-based growth and management’s decision to raise full-year revenue guidance. The letter also noted CYRX’s August 6, 2026 close at $14.71, $741.42 million market cap, and 52-week gain of 94.58%.
Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin
